Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222545 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
A Phase 2 study, sponsored by Omeros Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT02222545 is a Phase 2 study that has completed, run by Omeros Corporation. The registered enrollment target is 58 participants.
The verdict
NCT02222545, a Phase 2 study, has completed, sponsored by Omeros Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
Interventions
- BIOLOGICAL OMS721
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-11-02 |
| Est. Completion | 2020-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222545
The ClinicalTrials.gov registry entry for NCT02222545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OMS721 is the first listed.
NCT02222545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222545 about?
NCT02222545 is a clinical study titled "Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies". The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
What is the current status of trial NCT02222545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2014-11-02. Estimated completion is 2020-08-11.
What interventions are being tested in trial NCT02222545?
The interventions under investigation include: OMS721 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02222545?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.